ClinicalTrials.gg
CompletedNCT03275285IKEMAUpdated Feb 9, 2026Results posted

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

A Phase 3 interventional study of isatuximab SAR650984 and carfilzomib in Plasma Cell Myeloma, sponsored by Sanofi. Completed at 70 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Multiple Myeloma by Sanofi — 3 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · Sanofi.

Enrollment
5th of 34
302 · median 56
Started
2017
with 1 other
Phase 3
7 of 39
none open now
Registered
26th of 39
by date

Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 26th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

3 of the 39 studies in Multiple Myeloma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Multiple Myeloma by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.

Read the detailed description

The duration of the study for a patient will include a period for screening of up to 3 weeks. Patients will be treated until disease progression, unacceptable AE, or patient decision to stop the study treatment. After study treatment discontinuation, patients will have follow-up visits until the analysis of overall survival.

03

Conditions studied

  • Plasma Cell Myeloma

Browse trials for

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with MM previously treated with prior 1 to 3 lines and with measurable serum M-protein (>= 0.5 gram/deciliter) and/or urine M-protein (>= 200 milligram/24 hours).

Exclusion criteria

Exclusion criteria:

  • Participants previously pretreated with carfilzomib, who never achieved at least one minor response during previous therapies and/or last previous therapy completed within 14 last days.
  • Participants with serum free light chain (FLC) only.
  • Participants less than 18 years old, participants with performance status more than 2.
  • Participants with inadequate biological tests.
  • Participants with myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, class III or IV congestive heart failure, superior or equal to grade 3 arrhythmias, stroke or within last 6 months, and/or lower than 40%.
  • Participants with previous cancer unless disease free for more than 5 years or in situ cancer curatively treated.
  • Participants with known acquired immunodeficiency syndrome related illness or requiring antiretroviral treatment, or hepatitis A, B, or C active infection.
  • Women of or male participant with women of childbearing potential who do not agree to use highly effective method of .

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Isatuximab + Carfilzomib + Dexamethasone (IKd)

    Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth \[po\]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.

    Drug: isatuximab SAR650984 · Drug: carfilzomib · Drug: dexamethasone

  • Active comparator
    Carfilzomib + Dexamethasone (Kd)

    Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.

    Drug: carfilzomib · Drug: dexamethasone

Interventions

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Sarclisa

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Kyprolis

  • Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis

    Time (in months) from randomization to date of 1st documentation of progressive disease (PD)/date of death from any cause, whichever comes 1st. If PD \& death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever comes 1st. PD(IMWG criteria):any 1 of following:Increase(inc) of \>=25% in serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component \>=5 g/dL; and/or inc of \>=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if \>1 lesion/ \>=50% increase in longest diameter of previous soft tissue extramedullary disease lesion \>1 cm in short axis. Estimated by Kaplan-Meier method.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (median duration of follow-up was 20.73 months)

  2. Progression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis

    Time (in months) from randomization to date of 1st PD documentation/death date, whichever is 1st. If PD \& death not observed before cut-off date/date of further anti-myeloma treatment initiation, PFS censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever was 1st. Progression/deaths occurring \>8 weeks after last disease assessment censored at earliest date of last disease assessment without evidence of progression before initiation of new anti-myeloma treatment \& cut-off date. PD (IMWG criteria): meeting any 1: Inc \>=25% in Serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component \>=5 g/dL; and/or inc \>=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion \>1 cm short axis.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)

  3. Progression Free Survival as Determined by Independent Response Committee: Final Analysis

    PFS: time (in months) from randomization to date of first documentation of PD or date of death from any cause, whichever comes first. If PD and death are not observed before analysis cut-off date or date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment or analysis cut-off date, whichever comes first. PD as per IMWG criteria: any 1 of following: Inc of \>=25% in Serum M-component from nadir; serum M component increase \>=1 g/dL in 2 consecutive assessment, if starting M component was \>=5 g/dL; and/or inc of \>=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if \>1 lesion/ \>=50% inc in longest diameter of previous soft tissue extramedullary disease lesion \>1 cm in short axis. PFS estimated by Kaplan-Meier method.

    Time frame: From randomization until the final analysis data cut-off date of 14 January 2022 (the median duration of follow-up was 43.96 months)

  4. Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis

    Time (in months) from randomization to date of 1st documentation of PD/date of death from any cause, whichever comes 1st. If PD \& death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD/cut-off date, whichever comes 1st. Progressions/deaths occurring \>8 weeks after last disease assessment were censored at earliest date of last valid disease assessment not showing PD before initiation of further anti-myeloma treatment \& cut-off date. PD (per IMWG criteria): meeting any 1 criteria: Inc of \>=25% in serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component was \>=5 g/dL; and/or inc of \>=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion \>1 cm in short axis.

    Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)

Secondary outcomes

  1. Percentage of Participants With Overall Response (OR) as Determined by Independent Response Committee: Primary Analysis

    OR: participants with sCR, CR, VGPR \& partial response (PR) as best overall response assessed by IRC using IMWG response criteria (from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/cutoff date, whichever occurs 1st). sCR: negative immunofixation on serum \& urine, disappearance of soft tissue plasmacytoma, \<5% plasma cells in bone marrow aspirate (BMA) + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum \& urine, disappearance of soft tissue plasmacytoma, \<5% plasma cells in BMA. VGPR: serum \& urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein + urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR:\>=50% reduction of serum M-protein \& decrease in 24h urinary M-protein by \>=90%/\<200mg/24h, if present at baseline,\>=50% decrease in SPD of soft tissue plasmacytoma.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)

  2. Percentage of Participants With Very Good Partial Response (VGPR) or Better as Determined by Independent Response Committee: Primary Analysis

    VGPR or better: defined as participants with sCR, CR and VGPR as the best overall response (defined as best response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date whichever occurs first) as per IRC. As per IMWG response criteria: sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)

  3. Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Primary Analysis

    Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in bone marrow aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)

  4. Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Final Analysis

    Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in BM aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal FLC ratio, absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.

    Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)

  5. Percentage of Participants With Complete Response (CR) as Per Independent Response Committee: Final Analysis

    Complete response was defined as the participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal free light chain (FLC) ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with hydrashift isatuximab immunofixation electrophoresis (IFE) assay, which separated immunoglobulin G (IgG) isatuximab from IgG M protein.

    Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)

  6. Percentage of Participants With Complete Response With MRD Negativity: Final Analysis

    MRD negativity was defined as the percentage of participants for whom MRD was negative by next-generation sequencing at any timepoint after first dose of study treatment. Threshold for negativity is 10\^-5. MRD status in a participant was negative if at least one result of the assessment was negative in the participant otherwise MRD was considered as positive (MRD status reported as positive, missing or unevaluable). CR: participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with Hydrashift isatuximab IFE assay, which separated IgG isatuximab from IgG M protein.

    Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)

  7. Overall Survival (OS)

    Overall survival, defined as the time from the date of randomization to death from any cause. The data reported is based on cut-off date of 7 Feb 2023.

    Time frame: From randomization until the final analysis data cut-off date of 7 Feb 2023 (the median duration of follow-up was 56.61 months)

  8. Duration of Response (DOR): Primary Analysis

    DOR: time (in months) from date of 1st IRC determined response for participants achieving PR/better to date of 1st documented PD determined by IRC/death, whichever happens 1st. If disease progression/death before analysis cut-off date was not observed, DOR was censored at date of last valid disease assessment performed prior to initiation of further anti-myeloma treatment/data cut-off date, whichever was 1st. PD (IMWG criteria): inc of \>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute inc must be \>=0.5 g/dL), serum M-protein inc \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute inc must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>=50% inc in the longest diameter of previous lesion \>1 cm in short axis. PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90%/\<200mg/24 h. Estimated by Kaplan Meier method.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)

  9. Time to Progression (TTP): Primary Analysis

    TTP was defined as time in months from randomization to the date of first documentation of PD (as determined by the IRC). If progression was not observed before the analysis cut-off date or the date of initiation of further anti-myeloma treatment, TTP was censored at the date of the last valid disease assessment not showing disease progression performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. As per IMWG criteria, PD was defined for participants with inc of \>= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute inc must be \>= 0.5 g/dL), serum M-protein inc \>=1 g/dL if the lowest M component was \>=5 g/dL; urine M-component (the absolute inc must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>=50% inc in the longest diameter of a previous lesion \>1 centimeter in short axis.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)

  10. Time to First Response: Primary Analysis

    Time to first response was defined as the time (in months) from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. In the absence of response, participants were censored at the earliest of the date of the last valid disease assessment before disease progression or death, the date of the last valid disease assessment before initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. PR per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)

  11. Time to Best Response: Primary Analysis

    Time to best response was defined as time (in months) from randomization to the date of first occurrence of IRC determined as best overall response (PR or better) that is subsequently confirmed. In absence of response, participants were censored at earliest date of last valid disease assessment before disease progression/death, date of last valid disease assessment before initiation of further anti-myeloma treatment (if any)/ analysis cut-off date, whichever was 1st. PR (IMWG criteria) was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. Best Overall Response was defined as the best response, using the IRC's assessment of response, from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date, whichever occurs 1st.

    Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)

  12. Second Progression Free Survival (PFS2): Final Analysis - Data Cut-off Date of 14 Jan 2022

    PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of \>= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter short axis.

    Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)

  13. Second Progression Free Survival (PFS2): Overal Survival Analysis - Data Cut-off Date of 07 Feb 2023

    PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of \>= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter short axis.

    Time frame: From randomization until the overal survival analysis data cut-off date of 07 Feb 2023 (the median duration of follow-up was 56.61 months)

  14. Number of Participants With Renal Response (RR): Primary Analysis

    RR comprises of complete RR (CR renal), partial RR (PR renal) \& minor RR (MR renal). CR renal was defined as an improvement in estimated glomerular filtration rate (eGFR) from \<50 mL/min/1.73m\^2 at Baseline to \>=60 mL/min/1.73m\^2 in at least 1 assessment during the treatment period (time from first dose of study treatment up to 30 days after last dose of study treatment); PR renal was defined as improvement in eGFR from \<15 mL/min/1.73m\^2 at baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m\^2 during the on-treatment-period and MR renal was defined as an improvement in eGFR from \<15 mL/min/1.73m\^2 at Baseline to at least 1 assessment in the range of 15 to 30 mL/min/1.73m\^2 during the on-treatment-period or from 15 to 30 mL/min/1.73m\^2 at Baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m\^2 during the on-treatment-period.

    Time frame: From the first dose of study treatment to 30 days following the last administration of study treatment (maximum duration: up to 114 weeks)

  15. Health Related Quality of Life (HRQL): Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status Score at Specified Timepoints

    EORTC QLQ-C30 is a cancer-specific instrument that contains 30 items \& provides multidimensional assessment of HRQL. EORTC QLQ-C30 includes global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\[{Q29+Q30}/2\]-1)/6\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant. Results reported for primary analysis with data cut-off date 7-Feb-2020.

    Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)

  16. HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score at Specified Timepoints: Primary Analysis

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. Disease symptoms domain is one of the four domain scores. Disease symptoms domain consist of 6 questions and the score uses 4-point scale (1 'Not at All' to 4 'Very Much'). Disease Symptoms Domain Score is calculated as (\[{Q31+Q32+Q33+Q34+Q35+Q36}/6\]-1)/3\*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more symptoms and lower HRQL.

    Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)

  17. HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment at Specified Timepoints: Primary Analysis

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain consists of 10 questions and the score uses a 4-point scale (1 'Not at All' to 4 'Very Much'). Side Effects of Treatment Score (MYSE) is calculated as (\[{Q37+Q38+Q39+Q40+Q41+Q42+Q43+Q44+Q45+Q46}/10\]-1)/3\*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL.

    Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)

  18. HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Body Image Score at Specified Timepoints: Primary Analysis

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of one question and scores are based on the 4-point Likert scale ranging from "Not at all" to "Very much". Body image score is calculated as: (1 - \[Q47-1\]/3)\*100. Scores are averaged, and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.

    Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)

  19. HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Future Perspective at Specified Timepoints: Primary Analysis

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of three questions and the scores are based on the 4-point Likert scale ranging from "Not at all" to "Very much". Future Perspective score is calculated as (1 - (\[{Q48+Q49+Q50}/3\] -1)/3)\*100. Scores are averaged and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.

    Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)

  20. HRQL: Change From Baseline in European Quality of Life Group Questionnaire With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Health State Utility Index Value at Specified Timepoints: Primary Analysis

    The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist in 2 sections a descriptive system comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and Visual Analog Scale (VAS). Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.

    Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)

  21. HRQL: Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS) at Specified Timepoints: Primary Analysis

    The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist of 2 sections; descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). This information can be used as a quantitative measure of health as judged by the individual respondents.

    Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)

  22. Pharmacokinetics: Plasma Concentration at End of Infusion (Ceoi) of Isatuximab: Primary Analysis

    Ceoi is the plasma concentration observed at the end of intravenous infusion.

    Time frame: End of infusion on Cycle 1 Day 1 and Cycle 1 Day 15; Cycle 2 Day 1

  23. Pharmacokinetics: Plasma Concentration of Isatuximab at Ctrough: Primary Analysis

    Ctrough was the plasma concentration observed just before treatment administration during repeated dosing.

    Time frame: Pre-infusion on Cycle 1 Day 1, Day 8, Day 15 and Day 22, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and Cycle 10 Day 1

  24. Pharmacokinetics: Maximum Observed Concentration (Cmax) of Carfilzomib: Primary Analysis

    Cmax was defined as the maximum concentration observed after the first infusion calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 minutes (min), 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  25. Pharmacokinetics: Clast of Carfilzomib: Primary Analysis

    Clast was defined as the last concentration observed above the lower limit of quantification.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  26. Pharmacokinetics: Tmax of Carfilzomib: Primary Analysis

    Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  27. Pharmacokinetics: Tlast of Carfilzomib: Primary Analysis

    Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  28. Pharmacokinetics: Area Under the Plasma Concentration Time Curve (AUC) of Carfilzomib: Primary Analysis

    AUC was defined as area under the plasma concentration-time curve extrapolated to infinity according to the equation: AUC= AUClast + Clast/λz. AUC was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  29. Pharmacokinetics: Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) of Carfilzomib: Primary Analysis

    AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  30. Pharmacokinetics: Percentage of Extrapolation of AUC (AUCext) of Carfilzomib: Primary Analysis

    AUCext was defined as the percentage of the extrapolation of AUC, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  31. Pharmacokinetics: Terminal Half-life (t1/2z) of Carfilzomib: Primary Analysis

    T1/2 was defined as the time required for the concentration of the drug to reach half of its original value, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  32. Pharmacokinetics: Clearance at Steady State (CLss) of Carfilzomib: Primary Analysis

    CLss was defined as a quantitative measure of the rate at which a drug substance is removed from the body at steady state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  33. Pharmacokinetics: Volume of Distribution at Steady State (Vss) of Carfilzomib: Primary Analysis

    Volume of Distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss is the apparent volume of distribution at steady-state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

    Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15

  34. Number of Participants With Anti-Drug Antibodies (ADA): Primary Analysis

    ADA were categorized as: pre-existing, treatment induced, and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA with an increase in titer during the ADA on-study observation period.

    Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 111 weeks)

  35. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs): LPLV Analysis

    Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability / incapacity, was a congenital anomaly/birth defect, was a medically important event.

    Time frame: From first dose of study treatment administration (Day 1) up to 30 days post last dose of study treatment administration, up to 349 weeks for Kd arm and 356 weeks for IKd arm (maximum duration of treatment exposure)

07

Results

Posted Feb 13, 2023

Participant flow

Study was conducted at 69 active centers in 16 countries. A total of 341 participants were screened between 25 October 2017 and 21 March 2019, of which 39 participants were screen failure due to not meeting eligibility criteria. Randomization was stratified by number of prior lines (1 versus \>1) \& revised international staging system (R-ISS) I or II versus III versus not classified. Reason for not completed = Reason for definitive treatment discontinuation.

Participant flow — Overall Study
MilestoneCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Started123179
Treated122177
Completed00
Not completed123179
Withdrew: Adverse event2429
Withdrew: Progressive disease6886
Withdrew: Withdrawal by subject1821
Withdrew: Treatment extension study124
Withdrew: Randomized and not treated12
Withdrew: Study discontinuation15
Withdrew: Others1012

Outcome measures

SecondaryPercentage of Participants With Overall Response (OR) as Determined by Independent Response Committee: Primary Analysis

OR: participants with sCR, CR, VGPR \& partial response (PR) as best overall response assessed by IRC using IMWG response criteria (from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/cutoff date, whichever occurs 1st). sCR: negative immunofixation on serum \& urine, disappearance of soft tissue plasmacytoma, \<5% plasma cells in bone marrow aspirate (BMA) + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum \& urine, disappearance of soft tissue plasmacytoma, \<5% plasma cells in BMA. VGPR: serum \& urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein + urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR:\>=50% reduction of serum M-protein \& decrease in 24h urinary M-protein by \>=90%/\<200mg/24h, if present at baseline,\>=50% decrease in SPD of soft tissue plasmacytoma.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response (OR) as Determined by Independent Response Committee: Primary Analysis
percentage of participantsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Percentage of Participants With Overall Response (OR) as Determined by Independent Response Committee: Primary Analysis82.986.6
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Cochran-Mantel-Haenszel · p = 0.1930 (One-sided p-value based on Stratified Cochran-Mantel-Haenszel test. Threshold for statistical significance level at 0.025.)One sided p-value was stratified based on randomization factors according to IRT.
SecondaryPercentage of Participants With Very Good Partial Response (VGPR) or Better as Determined by Independent Response Committee: Primary Analysis

VGPR or better: defined as participants with sCR, CR and VGPR as the best overall response (defined as best response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date whichever occurs first) as per IRC. As per IMWG response criteria: sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Very Good Partial Response (VGPR) or Better as Determined by Independent Response Committee: Primary Analysis
percentage of participantsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Percentage of Participants With Very Good Partial Response (VGPR) or Better as Determined by Independent Response Committee: Primary Analysis56.172.6
SecondaryPercentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Primary Analysis

Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in bone marrow aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Reported as:
Number · percentage of participants
Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Primary Analysis
percentage of participantsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Primary Analysis13.029.6
SecondaryPercentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Final Analysis

Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in BM aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal FLC ratio, absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.

Time frame:
From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Reported as:
Number · percentage of participants
Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Final Analysis
percentage of participantsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Final Analysis13.833.5
SecondaryPercentage of Participants With Complete Response (CR) as Per Independent Response Committee: Final Analysis

Complete response was defined as the participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal free light chain (FLC) ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with hydrashift isatuximab immunofixation electrophoresis (IFE) assay, which separated immunoglobulin G (IgG) isatuximab from IgG M protein.

Time frame:
From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) as Per Independent Response Committee: Final Analysis
percentage of participantsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Percentage of Participants With Complete Response (CR) as Per Independent Response Committee: Final Analysis28.544.1
SecondaryPercentage of Participants With Complete Response With MRD Negativity: Final Analysis

MRD negativity was defined as the percentage of participants for whom MRD was negative by next-generation sequencing at any timepoint after first dose of study treatment. Threshold for negativity is 10\^-5. MRD status in a participant was negative if at least one result of the assessment was negative in the participant otherwise MRD was considered as positive (MRD status reported as positive, missing or unevaluable). CR: participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with Hydrashift isatuximab IFE assay, which separated IgG isatuximab from IgG M protein.

Time frame:
From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response With MRD Negativity: Final Analysis
percentage of participantsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Percentage of Participants With Complete Response With MRD Negativity: Final Analysis12.226.3
SecondaryOverall Survival (OS)

Overall survival, defined as the time from the date of randomization to death from any cause. The data reported is based on cut-off date of 7 Feb 2023.

Time frame:
From randomization until the final analysis data cut-off date of 7 Feb 2023 (the median duration of follow-up was 56.61 months)
Reported as:
Median · months
Overall Survival (OS)
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Overall Survival (OS)50.60 (38.932 to NA)NA (52.172 to NA)
SecondaryDuration of Response (DOR): Primary Analysis

DOR: time (in months) from date of 1st IRC determined response for participants achieving PR/better to date of 1st documented PD determined by IRC/death, whichever happens 1st. If disease progression/death before analysis cut-off date was not observed, DOR was censored at date of last valid disease assessment performed prior to initiation of further anti-myeloma treatment/data cut-off date, whichever was 1st. PD (IMWG criteria): inc of \>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute inc must be \>=0.5 g/dL), serum M-protein inc \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute inc must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>=50% inc in the longest diameter of previous lesion \>1 cm in short axis. PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90%/\<200mg/24 h. Estimated by Kaplan Meier method.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Reported as:
Median · months
Duration of Response (DOR): Primary Analysis
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Duration of Response (DOR): Primary AnalysisNA (14.752 to NA)NA (NA to NA)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Stratified hazard ratio: 0.425 · 95% CI 0.269 to 0.672Stratification was done on the number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.
SecondaryTime to Progression (TTP): Primary Analysis

TTP was defined as time in months from randomization to the date of first documentation of PD (as determined by the IRC). If progression was not observed before the analysis cut-off date or the date of initiation of further anti-myeloma treatment, TTP was censored at the date of the last valid disease assessment not showing disease progression performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. As per IMWG criteria, PD was defined for participants with inc of \>= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute inc must be \>= 0.5 g/dL), serum M-protein inc \>=1 g/dL if the lowest M component was \>=5 g/dL; urine M-component (the absolute inc must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>=50% inc in the longest diameter of a previous lesion \>1 centimeter in short axis.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Reported as:
Median · months
Time to Progression (TTP): Primary Analysis
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Time to Progression (TTP): Primary Analysis20.27 (16.986 to NA)NA (NA to NA)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Stratified hazard ratio: 0.495 · 95% CI 0.324 to 0.757Stratification was done on the number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.
SecondaryTime to First Response: Primary Analysis

Time to first response was defined as the time (in months) from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. In the absence of response, participants were censored at the earliest of the date of the last valid disease assessment before disease progression or death, the date of the last valid disease assessment before initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. PR per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Reported as:
Median · months
Time to First Response: Primary Analysis
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Time to First Response: Primary Analysis1.12 (1.051 to 1.183)1.08 (1.051 to 1.117)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Stratified hazard ratio: 1.143 · 95% CI 0.888 to 1.471
SecondaryTime to Best Response: Primary Analysis

Time to best response was defined as time (in months) from randomization to the date of first occurrence of IRC determined as best overall response (PR or better) that is subsequently confirmed. In absence of response, participants were censored at earliest date of last valid disease assessment before disease progression/death, date of last valid disease assessment before initiation of further anti-myeloma treatment (if any)/ analysis cut-off date, whichever was 1st. PR (IMWG criteria) was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. Best Overall Response was defined as the best response, using the IRC's assessment of response, from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date, whichever occurs 1st.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Reported as:
Median · months
Time to Best Response: Primary Analysis
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Time to Best Response: Primary Analysis3.78 (2.858 to 4.172)4.60 (3.811 to 5.257)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Stratified hazard ratio: 0.955 · 95% CI 0.740 to 1.233Stratification was done on the number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.
SecondarySecond Progression Free Survival (PFS2): Final Analysis - Data Cut-off Date of 14 Jan 2022

PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of \>= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter short axis.

Time frame:
From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Reported as:
Median · months
Second Progression Free Survival (PFS2): Final Analysis - Data Cut-off Date of 14 Jan 2022
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Second Progression Free Survival (PFS2): Final Analysis - Data Cut-off Date of 14 Jan 202235.58 (24.049 to 40.509)47.18 (38.111 to NA)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · [stratified hazard ratio]: 0.683 · 95% CI 0.496 to 0.941Stratification was done on the number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.
SecondarySecond Progression Free Survival (PFS2): Overal Survival Analysis - Data Cut-off Date of 07 Feb 2023

PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of \>= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter short axis.

Time frame:
From randomization until the overal survival analysis data cut-off date of 07 Feb 2023 (the median duration of follow-up was 56.61 months)
Reported as:
Median · months
Second Progression Free Survival (PFS2): Overal Survival Analysis - Data Cut-off Date of 07 Feb 2023
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Second Progression Free Survival (PFS2): Overal Survival Analysis - Data Cut-off Date of 07 Feb 202332.36 (23.129 to 40.016)47.18 (38.965 to 57.922)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Stratified hazard ratio: 0.663 · 95% CI 0.491 to 0.895Stratification was done on the number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.
SecondaryNumber of Participants With Renal Response (RR): Primary Analysis

RR comprises of complete RR (CR renal), partial RR (PR renal) \& minor RR (MR renal). CR renal was defined as an improvement in estimated glomerular filtration rate (eGFR) from \<50 mL/min/1.73m\^2 at Baseline to \>=60 mL/min/1.73m\^2 in at least 1 assessment during the treatment period (time from first dose of study treatment up to 30 days after last dose of study treatment); PR renal was defined as improvement in eGFR from \<15 mL/min/1.73m\^2 at baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m\^2 during the on-treatment-period and MR renal was defined as an improvement in eGFR from \<15 mL/min/1.73m\^2 at Baseline to at least 1 assessment in the range of 15 to 30 mL/min/1.73m\^2 during the on-treatment-period or from 15 to 30 mL/min/1.73m\^2 at Baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m\^2 during the on-treatment-period.

Time frame:
From the first dose of study treatment to 30 days following the last administration of study treatment (maximum duration: up to 114 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Renal Response (RR): Primary Analysis
ParticipantsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
CR Renal413
MR Renal14
SecondaryHealth Related Quality of Life (HRQL): Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status Score at Specified Timepoints

EORTC QLQ-C30 is a cancer-specific instrument that contains 30 items \& provides multidimensional assessment of HRQL. EORTC QLQ-C30 includes global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\[{Q29+Q30}/2\]-1)/6\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant. Results reported for primary analysis with data cut-off date 7-Feb-2020.

Time frame:
Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
Reported as:
Mean · score on a scale
Health Related Quality of Life (HRQL): Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status Score at Specified Timepoints
score on a scaleCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 2 Day 11.52 ± 21.11-1.60 ± 20.06
Cycle 3 Day 14.17 ± 22.920.05 ± 20.29
Cycle 4 Day 13.58 ± 21.20-1.89 ± 23.71
Cycle 5 Day 13.60 ± 21.80-1.23 ± 23.12
Cycle 6 Day 13.13 ± 20.50-1.44 ± 22.12
Cycle 7 Day 14.22 ± 22.55-1.77 ± 22.38
Cycle 8 Day 13.82 ± 21.71-1.06 ± 20.78
Cycle 9 Day 16.60 ± 19.28-0.78 ± 22.17
Cycle 10 Day 14.91 ± 21.55-1.21 ± 20.35
Cycle 11 Day 14.34 ± 20.06-1.10 ± 20.18
Cycle 12 Day 18.59 ± 22.370.84 ± 22.40
Cycle 13 Day 17.08 ± 19.76-1.26 ± 20.63
Cycle 14 Day 19.75 ± 21.62-0.98 ± 21.43
Cycle 15 Day 15.26 ± 22.140.16 ± 20.51
Cycle 16 Day 16.33 ± 20.73-1.07 ± 20.94
Cycle 17 Day 17.27 ± 21.040.00 ± 22.18
Cycle 18 Day 18.70 ± 23.16-0.36 ± 20.56
Cycle 19 Day 112.40 ± 21.42-1.23 ± 20.12
Cycle 20 Day 110.78 ± 20.97-1.05 ± 20.40
Cycle 21 Day 112.50 ± 21.81-1.85 ± 21.54
Cycle 22 Day 117.98 ± 22.270.31 ± 21.24
Cycle 23 Day 115.56 ± 22.023.15 ± 20.73
Cycle 24 Day 114.81 ± 26.280.38 ± 14.88
Cycle 25 Day 115.00 ± 28.503.13 ± 17.18
End of Treatment-6.14 ± 22.90-11.90 ± 25.86
SecondaryHRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score at Specified Timepoints: Primary Analysis

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. Disease symptoms domain is one of the four domain scores. Disease symptoms domain consist of 6 questions and the score uses 4-point scale (1 'Not at All' to 4 'Very Much'). Disease Symptoms Domain Score is calculated as (\[{Q31+Q32+Q33+Q34+Q35+Q36}/6\]-1)/3\*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more symptoms and lower HRQL.

Time frame:
Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
Reported as:
Mean · score on a scale
HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score at Specified Timepoints: Primary Analysis
score on a scaleCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 2 Day 1-5.34 ± 15.75-3.40 ± 19.58
Cycle 3 Day 1-8.28 ± 15.33-7.42 ± 18.15
Cycle 4 Day 1-5.45 ± 17.48-7.46 ± 17.99
Cycle 5 Day 1-5.78 ± 17.01-6.37 ± 18.32
Cycle 6 Day 1-6.11 ± 18.07-6.16 ± 19.88
Cycle 7 Day 1-6.64 ± 17.44-4.78 ± 20.77
Cycle 8 Day 1-6.94 ± 17.76-5.47 ± 19.96
Cycle 9 Day 1-5.65 ± 18.00-5.51 ± 17.86
Cycle 10 Day 1-5.56 ± 18.48-4.98 ± 17.24
Cycle 11 Day 1-3.24 ± 17.78-7.10 ± 17.57
Cycle 12 Day 1-5.30 ± 16.27-6.89 ± 17.58
Cycle 13 Day 1-7.69 ± 17.06-5.95 ± 16.44
Cycle 14 Day 1-8.66 ± 16.35-7.08 ± 17.98
Cycle 15 Day 1-5.56 ± 17.69-5.19 ± 17.84
Cycle 16 Day 1-8.06 ± 18.27-5.77 ± 18.66
Cycle 17 Day 1-7.57 ± 19.01-4.29 ± 19.73
Cycle 18 Day 1-7.16 ± 17.67-3.78 ± 17.93
Cycle 19 Day 1-7.18 ± 19.57-3.64 ± 16.70
Cycle 20 Day 1-11.93 ± 17.09-3.54 ± 21.63
Cycle 21 Day 1-9.72 ± 16.74-3.81 ± 19.70
Cycle 22 Day 1-9.94 ± 18.76-5.35 ± 22.48
Cycle 23 Day 1-5.56 ± 25.11-6.01 ± 19.53
Cycle 24 Day 1-6.17 ± 29.97-9.60 ± 18.16
Cycle 25 Day 1-12.22 ± 28.97-14.58 ± 21.65
End of Treatment2.35 ± 23.101.75 ± 23.48
SecondaryHRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment at Specified Timepoints: Primary Analysis

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain consists of 10 questions and the score uses a 4-point scale (1 'Not at All' to 4 'Very Much'). Side Effects of Treatment Score (MYSE) is calculated as (\[{Q37+Q38+Q39+Q40+Q41+Q42+Q43+Q44+Q45+Q46}/10\]-1)/3\*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL.

Time frame:
Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
Reported as:
Mean · score on a scale
HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment at Specified Timepoints: Primary Analysis
score on a scaleCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 2 Day 11.23 ± 11.561.41 ± 11.71
Cycle 3 Day 10.44 ± 10.110.84 ± 12.00
Cycle 4 Day 10.83 ± 11.380.99 ± 11.89
Cycle 5 Day 11.91 ± 11.362.36 ± 11.94
Cycle 6 Day 12.08 ± 11.811.61 ± 12.32
Cycle 7 Day 11.47 ± 12.142.14 ± 10.76
Cycle 8 Day 11.53 ± 12.072.86 ± 12.77
Cycle 9 Day 11.68 ± 11.571.49 ± 11.96
Cycle 10 Day 12.07 ± 11.622.68 ± 12.51
Cycle 11 Day 13.38 ± 12.002.03 ± 12.16
Cycle 12 Day 11.20 ± 10.523.04 ± 12.72
Cycle 13 Day 10.82 ± 10.222.12 ± 12.33
Cycle 14 Day 11.08 ± 10.561.71 ± 12.58
Cycle 15 Day 11.85 ± 11.451.87 ± 11.80
Cycle 16 Day 10.99 ± 10.542.58 ± 11.88
Cycle 17 Day 12.74 ± 10.034.10 ± 12.77
Cycle 18 Day 12.37 ± 10.512.95 ± 13.38
Cycle 19 Day 12.76 ± 11.412.16 ± 11.56
Cycle 20 Day 1-0.17 ± 10.622.05 ± 13.03
Cycle 21 Day 13.17 ± 10.612.74 ± 12.87
Cycle 22 Day 13.55 ± 6.461.51 ± 12.51
Cycle 23 Day 17.85 ± 9.93-1.39 ± 12.02
Cycle 24 Day 112.35 ± 7.17-2.54 ± 11.33
Cycle 25 Day 111.85 ± 4.06-3.50 ± 12.83
End of Treatment4.63 ± 13.015.56 ± 16.22
SecondaryHRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Body Image Score at Specified Timepoints: Primary Analysis

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of one question and scores are based on the 4-point Likert scale ranging from "Not at all" to "Very much". Body image score is calculated as: (1 - \[Q47-1\]/3)\*100. Scores are averaged, and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.

Time frame:
Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
Reported as:
Mean · score on a scale
HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Body Image Score at Specified Timepoints: Primary Analysis
score on a scaleCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 2 Day 1-1.29 ± 23.76-1.27 ± 21.31
Cycle 3 Day 11.98 ± 23.011.27 ± 26.84
Cycle 4 Day 1-1.65 ± 25.55-1.10 ± 28.04
Cycle 5 Day 1-0.69 ± 26.34-2.89 ± 27.29
Cycle 6 Day 1-1.83 ± 24.02-1.60 ± 26.93
Cycle 7 Day 1-0.77 ± 27.83-3.03 ± 24.36
Cycle 8 Day 1-5.16 ± 25.08-0.25 ± 24.84
Cycle 9 Day 1-2.14 ± 24.82-1.02 ± 25.80
Cycle 10 Day 1-1.80 ± 25.22-1.33 ± 25.54
Cycle 11 Day 1-1.85 ± 29.01-0.55 ± 23.47
Cycle 12 Day 1-2.05 ± 25.60-0.55 ± 25.09
Cycle 13 Day 1-3.89 ± 26.10-2.63 ± 21.79
Cycle 14 Day 1-4.52 ± 26.59-3.24 ± 25.57
Cycle 15 Day 10.00 ± 25.20-2.22 ± 24.58
Cycle 16 Day 1-1.31 ± 27.46-2.94 ± 22.55
Cycle 17 Day 1-1.42 ± 28.62-1.98 ± 26.17
Cycle 18 Day 11.48 ± 30.11-1.77 ± 24.62
Cycle 19 Day 10.00 ± 31.62-3.70 ± 26.18
Cycle 20 Day 10.00 ± 27.22-0.76 ± 24.75
Cycle 21 Day 1-4.76 ± 34.80-3.20 ± 26.74
Cycle 22 Day 1-8.77 ± 36.59-1.85 ± 27.02
Cycle 23 Day 1-13.33 ± 30.34-5.41 ± 24.23
Cycle 24 Day 1-25.93 ± 36.43-3.03 ± 25.01
Cycle 25 Day 1-53.33 ± 18.26-8.33 ± 25.82
End of Treatment-5.65 ± 21.58-9.36 ± 27.28
SecondaryHRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Future Perspective at Specified Timepoints: Primary Analysis

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of three questions and the scores are based on the 4-point Likert scale ranging from "Not at all" to "Very much". Future Perspective score is calculated as (1 - (\[{Q48+Q49+Q50}/3\] -1)/3)\*100. Scores are averaged and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.

Time frame:
Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
Reported as:
Mean · score on a scale
HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Future Perspective at Specified Timepoints: Primary Analysis
score on a scaleCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 2 Day 10.54 ± 19.337.57 ± 26.48
Cycle 3 Day 14.84 ± 22.089.70 ± 24.76
Cycle 4 Day 16.60 ± 20.448.55 ± 26.62
Cycle 5 Day 17.67 ± 22.647.56 ± 26.98
Cycle 6 Day 18.42 ± 21.819.97 ± 25.70
Cycle 7 Day 18.17 ± 21.938.47 ± 24.74
Cycle 8 Day 17.41 ± 22.5110.54 ± 24.50
Cycle 9 Day 17.26 ± 21.108.57 ± 28.26
Cycle 10 Day 18.56 ± 22.7911.56 ± 24.82
Cycle 11 Day 18.02 ± 21.6912.02 ± 24.23
Cycle 12 Day 16.84 ± 24.5111.48 ± 22.90
Cycle 13 Day 111.11 ± 20.0410.72 ± 23.18
Cycle 14 Day 18.85 ± 22.8611.31 ± 23.29
Cycle 15 Day 19.55 ± 24.1612.28 ± 22.27
Cycle 16 Day 112.42 ± 24.5111.76 ± 25.20
Cycle 17 Day 112.29 ± 21.6410.89 ± 25.29
Cycle 18 Day 111.36 ± 22.417.33 ± 23.25
Cycle 19 Day 19.21 ± 24.968.40 ± 25.50
Cycle 20 Day 110.13 ± 24.679.60 ± 25.34
Cycle 21 Day 110.32 ± 22.4110.65 ± 26.15
Cycle 22 Day 18.77 ± 25.2812.14 ± 22.35
Cycle 23 Day 19.63 ± 27.8112.61 ± 20.48
Cycle 24 Day 11.23 ± 24.5016.16 ± 18.70
Cycle 25 Day 1-4.44 ± 24.3415.28 ± 16.67
End of Treatment-3.95 ± 22.86-3.70 ± 31.45
SecondaryHRQL: Change From Baseline in European Quality of Life Group Questionnaire With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Health State Utility Index Value at Specified Timepoints: Primary Analysis

The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist in 2 sections a descriptive system comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and Visual Analog Scale (VAS). Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.

Time frame:
Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
Reported as:
Mean · score on a scale
HRQL: Change From Baseline in European Quality of Life Group Questionnaire With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Health State Utility Index Value at Specified Timepoints: Primary Analysis
score on a scaleCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 2 Day 10.05 ± 0.170.04 ± 0.19
Cycle 3 Day 10.06 ± 0.210.05 ± 0.22
Cycle 4 Day 10.02 ± 0.210.05 ± 0.21
Cycle 5 Day 10.04 ± 0.200.04 ± 0.20
Cycle 6 Day 10.03 ± 0.190.05 ± 0.23
Cycle 7 Day 10.06 ± 0.190.04 ± 0.21
Cycle 8 Day 10.06 ± 0.190.05 ± 0.22
Cycle 9 Day 10.05 ± 0.200.04 ± 0.19
Cycle 10 Day 10.06 ± 0.220.03 ± 0.22
Cycle 11 Day 10.04 ± 0.230.05 ± 0.20
Cycle 12 Day 10.03 ± 0.160.02 ± 0.20
Cycle 13 Day 10.06 ± 0.160.03 ± 0.19
Cycle 14 Day 10.06 ± 0.240.04 ± 0.19
Cycle 15 Day 10.05 ± 0.180.05 ± 0.18
Cycle 16 Day 10.06 ± 0.160.04 ± 0.19
Cycle 17 Day 10.05 ± 0.150.03 ± 0.20
Cycle 18 Day 10.02 ± 0.150.04 ± 0.17
Cycle 19 Day 10.03 ± 0.200.03 ± 0.18
Cycle 20 Day 10.06 ± 0.170.03 ± 0.23
Cycle 21 Day 10.03 ± 0.150.02 ± 0.22
Cycle 22 Day 10.05 ± 0.190.02 ± 0.22
Cycle 23 Day 10.05 ± 0.180.00 ± 0.27
Cycle 24 Day 10.04 ± 0.240.03 ± 0.20
Cycle 25 Day 10.05 ± 0.380.04 ± 0.22
End of Treatment-0.03 ± 0.25-0.08 ± 0.27
SecondaryHRQL: Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS) at Specified Timepoints: Primary Analysis

The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist of 2 sections; descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). This information can be used as a quantitative measure of health as judged by the individual respondents.

Time frame:
Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
Reported as:
Mean · score on a scale
HRQL: Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS) at Specified Timepoints: Primary Analysis
score on a scaleCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 2 Day 12.42 ± 17.040.60 ± 15.23
Cycle 3 Day 14.70 ± 16.133.47 ± 17.80
Cycle 4 Day 16.03 ± 16.732.29 ± 18.69
Cycle 5 Day 13.40 ± 16.892.35 ± 19.73
Cycle 6 Day 12.80 ± 18.561.24 ± 19.11
Cycle 7 Day 10.64 ± 21.692.24 ± 18.85
Cycle 8 Day 11.48 ± 17.112.40 ± 18.87
Cycle 9 Day 1-0.14 ± 17.462.93 ± 19.04
Cycle 10 Day 12.76 ± 17.412.82 ± 18.35
Cycle 11 Day 13.86 ± 20.073.77 ± 18.51
Cycle 12 Day 15.29 ± 18.513.63 ± 19.34
Cycle 13 Day 16.81 ± 19.574.94 ± 18.41
Cycle 14 Day 17.95 ± 18.124.72 ± 17.67
Cycle 15 Day 14.96 ± 18.923.23 ± 18.87
Cycle 16 Day 13.94 ± 18.784.56 ± 18.88
Cycle 17 Day 15.04 ± 17.934.97 ± 18.55
Cycle 18 Day 13.71 ± 19.083.83 ± 18.46
Cycle 19 Day 17.44 ± 18.733.69 ± 18.37
Cycle 20 Day 16.18 ± 18.434.20 ± 17.20
Cycle 21 Day 17.25 ± 23.463.26 ± 18.97
Cycle 22 Day 15.58 ± 24.062.35 ± 18.62
Cycle 23 Day 16.33 ± 18.736.44 ± 18.34
Cycle 24 Day 15.11 ± 17.934.50 ± 18.31
Cycle 25 Day 19.20 ± 21.485.00 ± 18.83
End of Treatment-4.40 ± 18.66-7.80 ± 21.08
SecondaryPharmacokinetics: Plasma Concentration at End of Infusion (Ceoi) of Isatuximab: Primary Analysis

Ceoi is the plasma concentration observed at the end of intravenous infusion.

Time frame:
End of infusion on Cycle 1 Day 1 and Cycle 1 Day 15; Cycle 2 Day 1
Reported as:
Mean · microgram/milliliter (mcg/mL)
Pharmacokinetics: Plasma Concentration at End of Infusion (Ceoi) of Isatuximab: Primary Analysis
microgram/milliliter (mcg/mL)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 1 Day 1274.01 ± 183.67
Cycle 1 Day 15380.28 ± 85.70
Cycle 2 Day 1522.74 ± 204.11
SecondaryPharmacokinetics: Plasma Concentration of Isatuximab at Ctrough: Primary Analysis

Ctrough was the plasma concentration observed just before treatment administration during repeated dosing.

Time frame:
Pre-infusion on Cycle 1 Day 1, Day 8, Day 15 and Day 22, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and Cycle 10 Day 1
Reported as:
Mean · mcg/mL
Pharmacokinetics: Plasma Concentration of Isatuximab at Ctrough: Primary Analysis
mcg/mLIsatuximab + Carfilzomib + Dexamethasone (IKd)
Cycle 1 Day 13.66 ± 34.40
Cycle 1 Day 882.14 ± 43.87
Cycle 1 Day 15180.02 ± 71.83
Cycle 1 Day 22252.63 ± 100.16
Cycle 2 Day 1324.28 ± 132.98
Cycle 3 Day 1295.78 ± 146.11
Cycle 4 Day 1342.48 ± 140.94
Cycle 5 Day 1389.25 ± 172.11
Cycle 6 Day 1427.16 ± 188.51
Cycle 7 Day 1433.22 ± 177.11
Cycle 8 Day 1490.51 ± 198.17
Cycle 9 Day 1486.07 ± 181.34
Cycle 10 Day 1490.08 ± 206.53
SecondaryPharmacokinetics: Maximum Observed Concentration (Cmax) of Carfilzomib: Primary Analysis

Cmax was defined as the maximum concentration observed after the first infusion calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 minutes (min), 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Mean · nanogram/milliliter (ng/mL)
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Carfilzomib: Primary Analysis
nanogram/milliliter (ng/mL)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Carfilzomib: Primary Analysis2090 ± 1360
SecondaryPharmacokinetics: Clast of Carfilzomib: Primary Analysis

Clast was defined as the last concentration observed above the lower limit of quantification.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Mean · ng/mL
Pharmacokinetics: Clast of Carfilzomib: Primary Analysis
ng/mLIsatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Clast of Carfilzomib: Primary Analysis3.00 ± 5.11
SecondaryPharmacokinetics: Tmax of Carfilzomib: Primary Analysis

Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Median · hours
Pharmacokinetics: Tmax of Carfilzomib: Primary Analysis
hoursIsatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Tmax of Carfilzomib: Primary Analysis0.54 (0.35 to 0.75)
SecondaryPharmacokinetics: Tlast of Carfilzomib: Primary Analysis

Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Median · hours
Pharmacokinetics: Tlast of Carfilzomib: Primary Analysis
hoursIsatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Tlast of Carfilzomib: Primary Analysis4.50 (2.52 to 4.75)
SecondaryPharmacokinetics: Area Under the Plasma Concentration Time Curve (AUC) of Carfilzomib: Primary Analysis

AUC was defined as area under the plasma concentration-time curve extrapolated to infinity according to the equation: AUC= AUClast + Clast/λz. AUC was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Mean · nanograms*hour/milliliter(ng*h/mL)
Pharmacokinetics: Area Under the Plasma Concentration Time Curve (AUC) of Carfilzomib: Primary Analysis
nanograms*hour/milliliter(ng*h/mL)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Area Under the Plasma Concentration Time Curve (AUC) of Carfilzomib: Primary Analysis784 ± 509
SecondaryPharmacokinetics: Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) of Carfilzomib: Primary Analysis

AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Mean · ng*h/mL
Pharmacokinetics: Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) of Carfilzomib: Primary Analysis
ng*h/mLIsatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) of Carfilzomib: Primary Analysis779 ± 505
SecondaryPharmacokinetics: Percentage of Extrapolation of AUC (AUCext) of Carfilzomib: Primary Analysis

AUCext was defined as the percentage of the extrapolation of AUC, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Geometric mean · percentage of AUC
Pharmacokinetics: Percentage of Extrapolation of AUC (AUCext) of Carfilzomib: Primary Analysis
percentage of AUCIsatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Percentage of Extrapolation of AUC (AUCext) of Carfilzomib: Primary Analysis0 ± 172
SecondaryPharmacokinetics: Terminal Half-life (t1/2z) of Carfilzomib: Primary Analysis

T1/2 was defined as the time required for the concentration of the drug to reach half of its original value, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Median · hours
Pharmacokinetics: Terminal Half-life (t1/2z) of Carfilzomib: Primary Analysis
hoursIsatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Terminal Half-life (t1/2z) of Carfilzomib: Primary Analysis0.860 (0.450 to 1.89)
SecondaryPharmacokinetics: Clearance at Steady State (CLss) of Carfilzomib: Primary Analysis

CLss was defined as a quantitative measure of the rate at which a drug substance is removed from the body at steady state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Mean · Liters/hour (L/h)
Pharmacokinetics: Clearance at Steady State (CLss) of Carfilzomib: Primary Analysis
Liters/hour (L/h)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Clearance at Steady State (CLss) of Carfilzomib: Primary Analysis466 ± 1190
SecondaryPharmacokinetics: Volume of Distribution at Steady State (Vss) of Carfilzomib: Primary Analysis

Volume of Distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss is the apparent volume of distribution at steady-state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.

Time frame:
Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Reported as:
Mean · Liters
Pharmacokinetics: Volume of Distribution at Steady State (Vss) of Carfilzomib: Primary Analysis
LitersIsatuximab + Carfilzomib + Dexamethasone (IKd)
Pharmacokinetics: Volume of Distribution at Steady State (Vss) of Carfilzomib: Primary Analysis453 ± 1570
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA): Primary Analysis

ADA were categorized as: pre-existing, treatment induced, and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA with an increase in titer during the ADA on-study observation period.

Time frame:
From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 111 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA): Primary Analysis
ParticipantsIsatuximab + Carfilzomib + Dexamethasone (IKd)
Pre-existing ADA0
Treatment induced ADA0
Treatment boosted ADA0
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs): LPLV Analysis

Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability / incapacity, was a congenital anomaly/birth defect, was a medically important event.

Time frame:
From first dose of study treatment administration (Day 1) up to 30 days post last dose of study treatment administration, up to 349 weeks for Kd arm and 356 weeks for IKd arm (maximum duration of treatment exposure)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs): LPLV Analysis
ParticipantsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Any TEAE119175
Any treatment emergent SAE74129
PrimaryProgression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis

Time (in months) from randomization to date of 1st documentation of progressive disease (PD)/date of death from any cause, whichever comes 1st. If PD \& death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever comes 1st. PD(IMWG criteria):any 1 of following:Increase(inc) of \>=25% in serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component \>=5 g/dL; and/or inc of \>=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if \>1 lesion/ \>=50% increase in longest diameter of previous soft tissue extramedullary disease lesion \>1 cm in short axis. Estimated by Kaplan-Meier method.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (median duration of follow-up was 20.73 months)
Reported as:
Median · months
Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis19.15 (15.770 to NA)NA (NA to NA)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Stratified Log-Rank test · p = 0.0007 (One-sided p-value based on Stratified log-rank test. Threshold for statistical significance at 0.005.) · Hazard ratio (hr): 0.531 · 99% CI 0.318 to 0.889Hazard Ratio was stratified on number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.
PrimaryProgression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis

Time (in months) from randomization to date of 1st PD documentation/death date, whichever is 1st. If PD \& death not observed before cut-off date/date of further anti-myeloma treatment initiation, PFS censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever was 1st. Progression/deaths occurring \>8 weeks after last disease assessment censored at earliest date of last disease assessment without evidence of progression before initiation of new anti-myeloma treatment \& cut-off date. PD (IMWG criteria): meeting any 1: Inc \>=25% in Serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component \>=5 g/dL; and/or inc \>=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion \>1 cm short axis.

Time frame:
From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Reported as:
Median · months
Progression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Progression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis20.27 (15.770 to NA)NA (NA to NA)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Stratified Log-Rank test · p = 0.0016 (One-sided p-value based on Stratified log-rank test. Threshold for statistical significance at 0.004.) · Hazard ratio (hr): 0.548 · 99.2% CI 0.317 to 0.948Hazard Ratio was stratified on number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.
PrimaryProgression Free Survival as Determined by Independent Response Committee: Final Analysis

PFS: time (in months) from randomization to date of first documentation of PD or date of death from any cause, whichever comes first. If PD and death are not observed before analysis cut-off date or date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment or analysis cut-off date, whichever comes first. PD as per IMWG criteria: any 1 of following: Inc of \>=25% in Serum M-component from nadir; serum M component increase \>=1 g/dL in 2 consecutive assessment, if starting M component was \>=5 g/dL; and/or inc of \>=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if \>1 lesion/ \>=50% inc in longest diameter of previous soft tissue extramedullary disease lesion \>1 cm in short axis. PFS estimated by Kaplan-Meier method.

Time frame:
From randomization until the final analysis data cut-off date of 14 January 2022 (the median duration of follow-up was 43.96 months)
Reported as:
Median · months
Progression Free Survival as Determined by Independent Response Committee: Final Analysis
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Progression Free Survival as Determined by Independent Response Committee: Final Analysis19.15 (15.770 to 25.035)35.65 (25.758 to 43.959)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Hazard ratio (hr): 0.576 · 95.4% CI 0.418 to 0.792Hazard Ratio was stratified on number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.
PrimaryProgression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis

Time (in months) from randomization to date of 1st documentation of PD/date of death from any cause, whichever comes 1st. If PD \& death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD/cut-off date, whichever comes 1st. Progressions/deaths occurring \>8 weeks after last disease assessment were censored at earliest date of last valid disease assessment not showing PD before initiation of further anti-myeloma treatment \& cut-off date. PD (per IMWG criteria): meeting any 1 criteria: Inc of \>=25% in serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component was \>=5 g/dL; and/or inc of \>=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion \>1 cm in short axis.

Time frame:
From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Reported as:
Median · months
Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis
monthsCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis20.76 (16.164 to 28.189)41.66 (27.138 to NA)
Statistical analysis
  • Carfilzomib + Dexamethasone (Kd) vs Isatuximab + Carfilzomib + Dexamethasone (IKd) · Hazard ratio (hr): 0.594 · 95.4% CI 0.424 to 0.832Hazard Ratio was stratified on number of prior lines of therapy (1 vs. \>1) and R-ISS stage (I or II vs. III vs. not classified) according to IRT.

Adverse events

Collected over AE data and deaths were collected during the whole study. TEAEs that developed, worsened, or became serious during the treatment period were assessed from first dose of study treatment administration (Day 1) up to 30 days post last dose of study treatment administration, up to 349 weeks for Kd arm and 356 weeks for IKd arm (maximum duration of treatment exposure).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carfilzomib + Dexamethasone (Kd)59/123 (48%)74/122 (60.7%)113/122 (92.6%)
Isatuximab + Carfilzomib + Dexamethasone (IKd)83/179 (46.4%)129/177 (72.9%)167/177 (94.4%)
Most frequent serious events
Showing 10 of 194
Most frequent serious events
EventCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
PneumoniaInfections and infestations17/12241/177
Lower Respiratory Tract InfectionInfections and infestations6/1228/177
InfluenzaInfections and infestations5/1222/177
Acute Kidney InjuryRenal and urinary disorders5/1223/177
Upper Respiratory Tract InfectionInfections and infestations2/1226/177
Cardiac FailureCardiac disorders4/1225/177
Deep Vein ThrombosisVascular disorders4/1223/177
Covid-19Infections and infestations1/1225/177
Pathological FractureMusculoskeletal and connective tissue disorders1/1225/177
Traumatic FractureInjury, poisoning and procedural complications2/1225/177
Most frequent other events
Showing 10 of 61
Most frequent other events
EventCarfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)
Infusion Related ReactionInjury, poisoning and procedural complications4/12280/177
Upper Respiratory Tract InfectionInfections and infestations32/12273/177
DiarrhoeaGastrointestinal disorders38/12272/177
HypertensionVascular disorders42/12269/177
FatigueGeneral disorders25/12257/177
DyspnoeaRespiratory, thoracic and mediastinal disorders28/12254/177
InsomniaPsychiatric disorders30/12246/177
BronchitisInfections and infestations14/12243/177
Back PainMusculoskeletal and connective tissue disorders25/12243/177
CoughRespiratory, thoracic and mediastinal disorders18/12241/177

Baseline characteristics

Analysis was performed on randomized population.

Age, Continuous
Age, Continuous(years)Carfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)Total
Mean62.9 ± 10.063.3 ± 9.863.1 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Carfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)Total
Female5578133
Male68101169
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Carfilzomib + Dexamethasone (Kd)Isatuximab + Carfilzomib + Dexamethasone (IKd)Total
American Indian or Alaska Native000
Asian242650
Native Hawaiian or Other Pacific Islander000
Black or African American459
White83131214
More than one race033
Unknown or Not Reported121426
08

Study locations

70 sites
  • UCSF MS Center Site Number : 8400002
    San Francisco, California 94117, United States
  • Spartanburg Medical Center Site Number : 8400003
    Spartanburg, South Carolina 29303-3040, United States
  • Investigational Site Number : 0360005
    Blacktown, New South Wales 2148, Australia
  • Investigational Site Number : 0360006
    Tweed Heads, New South Wales 2485, Australia
  • Investigational Site Number : 0360002
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number : 0360001
    Fitzroy, Victoria 3065, Australia
  • Investigational Site Number : 0360004
    Heidelberg West, Victoria 3081, Australia
  • Investigational Site Number : 0360007
    Nedlands, Western Australia 6009, Australia
  • Investigational Site Number : 0360008
    West Perth, Western Australia 6005, Australia
  • Hospital Sao Rafael - Rede D'OR Sao Luiz Site Number : 0760005
    Salvador, Estado de Bahia 41253-900, Brazil
  • Hospital Mae de Deus Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • Hospital de Amor - Hospital do Cancer de Barretos - Fundacao Pio XII Site Number : 0760001
    Barretos, São Paulo 14784-400, Brazil
  • Hospital das Clinicas de Sao Paulo Site Number : 0760002
    São Paulo, São Paulo 05403-000, Brazil
  • Instituto COI de Educacao e Pesquisa Site Number : 0760004
    Rio de Janeiro, 22775-002, Brazil
  • Investigational Site Number : 1240003
    Surrey, British Columbia V3V 1Z2, Canada
  • Investigational Site Number : 1240001
    Saint John, New Brunswick E2L 4L2, Canada
  • Investigational Site Number : 1240002
    Montreal, Quebec H1T 2M4, Canada
  • Investigational Site Number : 2030002
    Brno, 62500, Czechia
  • Investigational Site Number : 2030004
    Olomouc, 77900, Czechia
  • Investigational Site Number : 2030003
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number : 2030001
    Prague, 12808, Czechia
  • Investigational Site Number : 2500003
    Lille, 59037, France
  • Investigational Site Number : 2500001
    Nantes, 44093, France
  • Investigational Site Number : 2500006
    Paris, 75012, France
  • Investigational Site Number : 2500002
    Pessac, 33600, France
  • Investigational Site Number : 2500005
    Pierre-Bénite, 69495, France
  • Investigational Site Number : 2500004
    Poitiers, 86021, France
  • Investigational Site Number : 3000002
    Athens, 10676, Greece
  • Investigational Site Number : 3000005
    Athens, 11527, Greece
  • Investigational Site Number : 3000001
    Athens, 11528, Greece
  • Investigational Site Number : 3000004
    Pátrai, 26504, Greece
  • Investigational Site Number : 3000003
    Thessaloniki, 57010, Greece
  • Investigational Site Number : 3480003
    Budapest, 1083, Hungary
  • Investigational Site Number : 3480001
    Budapest, 1097, Hungary
  • Investigational Site Number : 3480004
    Budapest, 1125, Hungary
  • Investigational Site Number : 3480005
    Kaposvár, 7400, Hungary
  • Investigational Site Number : 3800003
    Bologna, 40138, Italy
  • Investigational Site Number : 3800001
    Pisa, 56126, Italy
  • Investigational Site Number : 3800004
    Reggio Emilia, 42123, Italy
  • Investigational Site Number : 3800002
    Torino, 10126, Italy
  • Investigational Site Number : 3920005
    Shiwa-gun, Iwate 028-3695, Japan
  • Investigational Site Number : 3920007
    Kumamoto, Kumamoto 860-8556, Japan
  • Investigational Site Number : 3920001
    Suwa-shi, Nagano 392-8510, Japan
  • Investigational Site Number : 3920003
    Sunto-gun, Shizuoka 411-8777, Japan
  • Investigational Site Number : 3920004
    Shibuya-ku, Tokyo 150-8935, Japan
  • Investigational Site Number : 3920006
    Shinjuku-ku, Tokyo 162-8666, Japan
  • Investigational Site Number : 3920002
    Yamagata, 990-9585, Japan
  • Investigational Site Number : 5540001
    Auckland, 1640, New Zealand
  • Investigational Site Number : 5540002
    Wellington, 6021, New Zealand
  • Investigational Site Number : 6430003
    Kirov, 610027, Russia
  • Investigational Site Number : 6430004
    Novosibirsk, 630047, Russia
  • Investigational Site Number : 6430002
    Yekaterinburg, 620102, Russia
  • Investigational Site Number : 4100006
    Busan, Busan 602-715, South Korea
  • Investigational Site Number : 4100002
    Gangnam-gu, Seoul-teukbyeolsi 06351, South Korea
  • Investigational Site Number : 4100001
    Seoul, Seoul-teukbyeolsi 03080, South Korea
  • Investigational Site Number : 4100004
    Seoul, Seoul-teukbyeolsi 03722, South Korea
  • Investigational Site Number : 4100005
    Seoul, 06591, South Korea
  • Investigational Site Number : 7240001
    Badalona, Catalunya [Cataluña] 08916, Spain
  • Investigational Site Number : 7240005
    Barcelona, Catalunya [Cataluña] 08036, Spain
  • Investigational Site Number : 7240002
    Valencia, Valenciana, Comunidad 46017, Spain
  • Investigational Site Number : 7240003
    Madrid, 28041, Spain
  • Investigational Site Number : 7240004
    Seville, 41013, Spain
  • Investigational Site Number : 7920003
    Adana, 01250, Turkey (Türkiye)
  • Investigational Site Number : 7920001
    Ankara, 06500, Turkey (Türkiye)
  • Investigational Site Number : 7920005
    Bursa, 16059, Turkey (Türkiye)
  • Investigational Site Number : 7920002
    Istanbul, 34381, Turkey (Türkiye)
  • Investigational Site Number : 7920004
    Samsun, 55139, Turkey (Türkiye)
  • Investigational Site Number : 8260004
    Plymouth, Devon PL6 8DH, United Kingdom
  • Investigational Site Number : 8260005
    Leicester, Leicestershire LE1 5WW, United Kingdom
  • Investigational Site Number : 8260001
    Bristol, Somerset BS2 8ED, United Kingdom
09

References and documents

Publications

  • Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Spicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Mace S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. PubMed 34097854 ↗
  • Martin TG, Capra M, Mohty M, Suzuki K, Quach H, Cavo M, Moreau P, Dimopoulos M, Yong K, Tekle C, Foster MC, Barnes Y, Risse ML, Mikhael J. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. Transplant Cell Ther. 2023 Feb;29(2):134.e1-134.e7. doi: 10.1016/j.jtct.2022.11.005. Epub 2022 Nov 11. PubMed 36372355 ↗
  • Chami B, Okuda M, Moayeri M, Pirenne F, Hidaka Y, Nambiar A, Song Z, Bedel O, Zhang B, Hopke J, Deng G, Zhu C, Mace S, Chiron M, Adrian F, Fukao T, Basile FG, Martin T. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping. Transfusion. 2022 Nov;62(11):2334-2348. doi: 10.1111/trf.17137. Epub 2022 Oct 14. PubMed 36239134 ↗
  • Yong K, Martin T, Dimopoulos MA, Mikhael J, Capra M, Facon T, Hajek R, Spicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Mace S, Moreau P. Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone. Future Oncol. 2026 Jun;22(15):1737-1749. doi: 10.1080/14796694.2026.2683336. Epub 2026 Jun 27. PubMed 42363804 ↗
  • Yong K, Martin T, Dimopoulos MA, Mikhael J, Capra M, Facon T, Hajek R, Spicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Mace S, Risse ML, Moreau P. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial. Lancet Haematol. 2024 Oct;11(10):e741-e750. doi: 10.1016/S2352-3026(24)00148-0. Epub 2024 Jul 24. PubMed 39067465 ↗
  • Thoren K, Menad S, Nouadje G, Mace S. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma. J Appl Lab Med. 2024 Jul 1;9(4):661-671. doi: 10.1093/jalm/jfae028. PubMed 38573925 ↗
  • Facon T, Moreau P, Baker R, Min CK, Leleu X, Mohty M, Karlin L, Armstrong NM, Tekle C, Schwab S, Risse ML, Martin T. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. Haematologica. 2024 Feb 1;109(2):604-616. doi: 10.3324/haematol.2023.283073. PubMed 37584290 ↗
  • Kawano Y, Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim JS, Moreau P, Martin T, Tada K, Risse ML, Suzuki K. Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e360-e367. doi: 10.1016/j.clml.2023.06.011. Epub 2023 Jul 3. PubMed 37479547 ↗
  • Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Spicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Mace S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8. PubMed 37156782 ↗
  • Beksac M, Spicka I, Hajek R, Bringhen S, Jelinek T, Martin T, Mikala G, Moreau P, Symeonidis A, Rawlings AM, van de Velde H, Richardson PG. Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. Leuk Res. 2022 Nov;122:106948. doi: 10.1016/j.leukres.2022.106948. Epub 2022 Sep 6. PubMed 36108425 ↗
  • Moreau P, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset G, Martin T. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. Future Oncol. 2020 Jan;16(2):4347-4358. doi: 10.2217/fon-2019-0431. Epub 2019 Dec 13. PubMed 31833394 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jan 2022, 50 months.

Results were first posted in Feb 2023, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 50 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2017
First posted
Sep 7, 2017
StartActual
Oct 25, 2017
Primary completionActual
Jan 14, 2022
CompletionActual
Jan 3, 2025
Results first posted
Feb 13, 2023
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03275285
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 7, 2017
Start date
Oct 25, 2017
Primary completion
Jan 14, 2022
Completion
Jan 3, 2025
Results posted
Feb 13, 2023
Last update
Feb 9, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion